Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.02.031
Abstract: To the Editor: Secukinumab, an interleukin 17A inhibitor approved for the treatment of moderate-tosevere plaque psoriasis, has shown high levels of clinical efficacy and a favorable safety profile in both short-term and long-term clinical trials.… read more here.
Keywords: drug survival; study; drug; secukinumab drug ... See more keywords